-$0.40 EPS Expected for NewLink Genetics Corp (NLNK) This Quarter

Share on StockTwits

Wall Street brokerages predict that NewLink Genetics Corp (NASDAQ:NLNK) will announce earnings per share (EPS) of ($0.40) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for NewLink Genetics’ earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.49). NewLink Genetics reported earnings per share of ($0.69) during the same quarter last year, which would suggest a positive year-over-year growth rate of 42%. The firm is expected to report its next quarterly earnings results on Thursday, November 1st.

According to Zacks, analysts expect that NewLink Genetics will report full-year earnings of ($1.69) per share for the current year, with EPS estimates ranging from ($1.90) to ($1.56). For the next year, analysts anticipate that the business will post earnings of ($0.93) per share, with EPS estimates ranging from ($1.58) to $0.58. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover NewLink Genetics.

NewLink Genetics (NASDAQ:NLNK) last posted its quarterly earnings results on Tuesday, July 31st. The biotechnology company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.12. NewLink Genetics had a negative net margin of 252.18% and a negative return on equity of 53.70%. The firm had revenue of $2.25 million for the quarter, compared to analyst estimates of $5.85 million.

Several research firms recently commented on NLNK. Zacks Investment Research upgraded shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Saturday, August 4th. Stifel Nicolaus lowered shares of NewLink Genetics from a “buy” rating to a “hold” rating and cut their price target for the company from $8.00 to $4.00 in a report on Wednesday, August 1st. Finally, ValuEngine lowered shares of NewLink Genetics from a “sell” rating to a “strong sell” rating in a report on Friday, June 22nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $9.64.

NASDAQ NLNK opened at $2.37 on Tuesday. NewLink Genetics has a one year low of $2.31 and a one year high of $12.91.

In other news, Director Ernest Talarico III sold 13,806 shares of NewLink Genetics stock in a transaction that occurred on Tuesday, July 10th. The shares were sold at an average price of $4.82, for a total transaction of $66,544.92. Following the sale, the director now owns 39,365 shares in the company, valued at $189,739.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 12.30% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Quantitative Systematic Strategies LLC purchased a new stake in shares of NewLink Genetics during the second quarter valued at approximately $133,000. Alambic Investment Management L.P. purchased a new stake in shares of NewLink Genetics during the first quarter valued at approximately $384,000. Northwest Wealth Management LLC purchased a new stake in shares of NewLink Genetics during the second quarter valued at approximately $266,000. Pennsylvania Trust Co purchased a new stake in shares of NewLink Genetics during the second quarter valued at approximately $395,000. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of NewLink Genetics by 19.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 120,595 shares of the biotechnology company’s stock valued at $875,000 after purchasing an additional 19,651 shares during the period. Institutional investors own 42.01% of the company’s stock.

About NewLink Genetics

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.

Further Reading: Intrinsic Value

Get a free copy of the Zacks research report on NewLink Genetics (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.